Other support of the vitamin D pathway on prostate cancer prognosis is that genetic variants in the vitamin D receptor are associated with Gleason score [14], genetic variants in the vitamin D pathway are associated with risk of recurrence/progression and prostate cancer-specific mortality [15], and the high expression of the vitamin D receptor in prostatectomy specimens is associated with better prognosis [28]. This evidence concerns the gene VDR and prostate cancer.